Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
APEX-Breast01
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- NCT06561607 ↗
- Active, not recruiting
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Focused
We haven't built an HCP commentary report on APEX-Breast01 (TQB2102 for in Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on APEX-Breast01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- TQB2102 for Injection; Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
- Arms
- TQB2102 for Injection · Experimental
- Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) · Active comparator
- Enrollment
- 542 (estimated)
- Primary outcomes
- Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Start
- Oct 11, 2024
- Primary completion
- Jan 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06561607 · updated Sep 10, 2026